An interventional study of Afternoon Nap and Caffeine in Athletic Performance, Sports Performance and Exercise Performance, sponsored by The Higher Institute of Sport and Physical Education of Sfax. Completed at 1 site in Tunisia. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by The Higher Institute of Sport and Physical Education of Sfax · Not applicable, Interventional, and Other
This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes.
Participants completed five experimental conditions in a randomised crossover design: placebo without napping, napping with placebo, caffeine without napping, napping combined with caffeine, and napping combined with caffeine plus a standardised active recovery and nutritional protocol. The nap opportunity lasted 90 minutes and caffeine was administered at 5 mg/kg body mass.
The main outcome was repeated agility performance. Additional outcomes included sprint performance, jumping performance, reaction time, subjective sleepiness, sleep characteristics during the nap opportunity, and selected physiological measures. The study also explored whether responses differed according to sex and chronotype.
This randomised, placebo-controlled crossover study examined the isolated and combined effects of afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol on evening athletic performance.
Participants completed five experimental conditions in a counterbalanced Latin-square order, with at least 72 h between sessions:
The active recovery and nutritional protocol included a standardised lower-limb dynamic stretching routine followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. The protocol was identical for all participants allocated to this condition.
Participants were stratified by sex and chronotype before condition allocation. Capsule allocation was double-blinded: participants, outcome assessors, and the testing team were unaware of whether caffeine or placebo had been administered. Blinding of nap and active recovery components was not possible because of the nature of these interventions.
The primary outcome was total time during the Repeated Modified Agility Test. Secondary performance outcomes included 20-m sprint time, countermovement jump height, squat jump height, simple reaction time, choice reaction time, and subjective sleepiness. Nap sleep characteristics were assessed using portable electroencephalographic monitoring. Physiological measures included heart-rate variability, salivary cortisol, plasma brain-derived neurotrophic factor, and blood lactate.
All sessions were conducted under standardised sleep, dietary, and activity-control procedures. The study explored whether intervention responses differed by sex and chronotype.
The Higher Institute of Sport and Physical Education of Sfax is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo capsule (microcrystalline cellulose) at 18:00, no nap opportunity
Other: Placebo
90-minute afternoon nap opportunity (13:00-14:30) with objective sleep architecture recording via portable EEG headband (Dreem 3), followed by placebo capsule (microcrystalline cellulose) at 18:00. Participants remained in a quiet, dimly lit room during the nap opportunity.
Behavioral: Afternoon Nap · Other: Placebo
Caffeine ingestion (5 mg/kg body mass of anhydrous caffeine) at 18:00, no nap opportunity. Participants remained in a quiet, dimly lit room during the 13:00-14:30 period.
Dietary Supplement: Caffeine
90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, followed by caffeine ingestion (5 mg/kg) at 18:00.
Behavioral: Afternoon Nap · Dietary Supplement: Caffeine
90-min afternoon nap opportunity (13:00-14:30) with portable EEG monitoring, caffeine ingestion (5 mg/kg body mass) at 18:00, and a 15-min standardised active recovery and nutritional protocol from 18:45 to 19:00. The protocol included lower-limb dynamic stretching followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate.
Behavioral: Afternoon Nap · Dietary Supplement: Caffeine · Combination Product: Standardised Active Recovery and Nutritional Protocol
A 90-min afternoon nap opportunity from 13:00 to 14:30 in a quiet, dimly lit, temperature-controlled room. Sleep was monitored using a portable EEG headband. Participants were provided with earplugs and eye masks, and nap sleep characteristics, including sleep stages, were recorded.
Anhydrous caffeine (5 mg/kg body mass) was administered orally in an opaque capsule at 18:00. Placebo capsules contained microcrystalline cellulose and were matched for appearance, mass, colour, and odour. Capsule allocation was blinded to participants and outcome assessors.
A 15-min standardised active recovery and nutritional protocol performed from 18:45 to 19:00. It included lower-limb dynamic stretching exercises (forward/backward and lateral leg swings, walking lunges, high knees, and butt kicks; 10 repetitions per leg at a controlled pace), followed by ingestion of a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate mixed with 200 mL water.
Microcrystalline cellulose was administered orally in an opaque capsule at 18:00. Placebo capsules were matched to caffeine capsules for appearance, mass, colour, and odour.
Repeated Modified Agility Test (RMAT) Total Time
Total time (seconds) to complete 10 maximal 20-m sprints with four changes of direction (forward sprint, left shuffle, right shuffle, backward sprint). The test was conducted on an indoor hardwood court using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start/finish line. Participants started from a standing position 0.5 m behind the first photocell. Lower values indicate better repeated agility performance. This was the primary outcome measure used for sample size calculation.
Time frame: At approximately 19:35 on each of the five experimental days
Countermovement Jump (CMJ) Height
Maximum jump height (cm) calculated from flight time using the formula h = g·t²/8, where g = 9.81 m·s-². Participants started from an upright standing position, performed a rapid downward movement to approximately 90° knee flexion, and immediately jumped vertically, maintaining hands on hips throughout. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained. Measured using an optical measurement system (Optojump Next, Microgate SRL, Bolzano, Italy) with a sampling frequency of 1000 Hz. Higher values indicate better explosive lower-limb performance.
Time frame: At approximately 19:20 on each of the five experimental days.
Squat Jump (SJ) Height
Maximum jump height (cm) from a static squat position with knees at approximately 90° flexion, hands on hips. Participants held the starting position for 2-3 seconds before jumping vertically without any countermovement. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained for analysis. Calculated from flight time using h = g·t²/8. Measured using Optojump Next optical system (1000 Hz sampling frequency). Higher values indicate better explosive lower-limb performance without stretch-shortening cycle contribution.
Time frame: At approximately 19:25 on each of the five experimental days.
20-m Sprint Time
Best time (seconds) of two maximal 20-m sprints from a standing start, with 3 minutes of passive recovery between sprints. Participants started 0.5 m behind the start line. Sprint time was measured using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start (0 m) and finish (20 m) lines. Lower values indicate better linear sprint performance.
Time frame: At approximately 19:45 on each of the five experimental days.
Simple Reaction Time (SRT)
Mean reaction time (milliseconds) across 15 recorded trials. A green circle appeared on a black background on a 15-inch laptop screen (60 Hz refresh rate), and participants pressed the space bar as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster simple reaction time and better cognitive processing speed.
Time frame: At approximately 19:15 on each of the five experimental days.
Choice Reaction Time (CRT)
Mean reaction time (milliseconds) across 15 recorded trials. Either a red circle (press the left arrow key) or a blue square (press the right arrow key) appeared randomly on a 15-inch laptop screen (60 Hz refresh rate). Participants had to identify the stimulus and press the correct key as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster choice reaction time and better cognitive decision-making speed.
Time frame: At approximately 19:20 on each of the five experimental days.
Heart Rate Variability (RMSSD and HF Power)
Heart-rate variability was recorded during 5-min supine resting measurements with spontaneous breathing using a Polar H10 chest strap. RR intervals were analysed using Kubios HRV software after artefact correction. The main HRV variables were RMSSD (ms) and high-frequency power (0.15-0.40 Hz, normalised units).
Time frame: At 12:00, 18:00, and approximately 19:45 on each of the five experimental days.
Salivary Cortisol Concentration
Salivary cortisol concentration (nmol/L) measured using Salivette cotton swabs (Sarstedt, Nümbrecht, Germany). Participants were instructed to avoid eating, drinking (except water), and brushing teeth for 30 minutes before each sample. Samples were centrifuged at 1500×g for 10 minutes at 4°C, and the supernatant was stored at -80°C until analysis. Cortisol concentration was measured in duplicate using a high-sensitivity enzyme-linked immunosorbent assay (ELISA, IBL International, Hamburg, Germany) with a detection limit of 0.05 ng/mL and intra- and inter-assay coefficients of variation \< 8%. Lower values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activity.
Time frame: At 12:00, 18:00, approximately 19:45, and 30 minutes after exercise on each of the five experimental days.
Plasma Brain-Derived Neurotrophic Factor (BDNF)
BDNF concentration (pg/mL) measured in venous blood samples (5 mL) drawn from an antecubital vein. Blood was collected into EDTA tubes, immediately centrifuged at 1500×g for 15 minutes at 4°C, and plasma was stored at -80°C until analysis. BDNF concentration was quantified using a commercially available ELISA kit (R\&D Systems, Minneapolis, MN, USA; catalogue number DBD00) with a detection limit of 20 pg/mL and intra- and inter-assay CVs \< 6% and \< 9%, respectively. Higher values indicate greater neurotrophic activity.
Time frame: Measured at baseline and after completion of the evening testing battery on each experimental day.
Blood Lactate Concentration
Lactate concentration (mmol/L) measured in capillary blood samples (5 µL) collected from the fingertip using a Lactate Pro 2 analyzer (Arkray, Kyoto, Japan), which has a coefficient of variation \< 3%. Higher values indicate greater metabolic perturbation and glycolytic activation during high-intensity exercise.
Time frame: At 18:55, 3 minutes after the Repeated Modified Agility Test, and 3 minutes after the 20-m sprint on each of the five experimental days.
Nap Architecture (EEG)
Objective sleep parameters recorded using a validated dry-electrode portable EEG headband (Dreem 3, Paris, France) with six channels (F3, F4, C3, C4, O1, O2, referenced to linked mastoids). Sleep stages were automatically scored in 30-second epochs using the manufacturer's algorithm and visually corrected by a certified sleep technologist blinded to condition and participant. Parameters extracted: total sleep time (TST, minutes), sleep onset latency (SOL, minutes), time in N2 sleep (minutes), time in N3 slow-wave sleep (minutes), time in REM sleep (minutes), and sleep efficiency (TST/time in bed × 100, %).
Time frame: During the 90-minute nap opportunity from 13:00 to 14:30 on NAP, NAP+CAF, and NAP+CAF+REC condition days only.
Plan to share: Yes — Anonymised individual participant data (IPD) will be shared for all 60 participants across all five experimental conditions (300 experimental sessions). Data will include: demographic characteristics, anthropometric measures, chronotype classification (MEQ scores), sleep quality (PSQI scores), nap architecture (EEG-derived sleep stages), physical performance outcomes (RMAT, CMJ, SJ, 20-m sprint), cognitive performance outcomes (SRT, CRT), subjective sleepiness (ESS, KSS), and physiological biomarkers (HRV-RMSSD, HF power, salivary cortisol, plasma BDNF, blood lactate). All data will be fully anonymised using coded identifiers (S01-S60), with the identification key stored separately on encrypted institutional servers.
Supporting information: Study protocol, Sap, Icf, Analytic code
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Higher Institute of Sport and Physical Education of Sfax